Click here to print this page

Planning Retirement Online

Cancer wonder drug not available on NHS

If you read this week’s Daily Mail, you will have seen the story that NICE (Britain’s National Institute for Health and Care Excellence) has announced that the new cancer wonder drug Nivolumab is too expensive and so won’t be available in England and Wales.

Nivolumab has shown to be twice as effective as chemotherapy with far fewer side effects.

To be told you have a life threatening disease is of course totally devastating. But to then be told there is a drug that could help or even stop it progressing, but you can’t have it because Britain can’t afford the cost must be even more shattering.

But here at Laterlife we remembered a breaking story just last July when it was announced that Nivolumab had been approved for lung cancer through the UK’s early access to medicine’s scheme and had been given an EU license for melanoma.

So does this mean that some patients can still have access to this breakthrough treatment.

Laterlife decided to find out the facts and contacted NICE.

They told Laterlife:

“Our independent advisory committee recognised that Nivolumab is a promising new treatment. However, even allowing for the extra flexibility they have for making recommendations about new cancer treatments, it could not be considered a cost effective use of NHS resources.”

However, NICE  has also told us that they are today (Dec 16th) opening a consultation on  preliminary draft guidance on Nivolumab (marketed as Opdivo by Bristol-Myers Squibb) to treat a specific type of lung cancer known as squamous cell, which is advanced or has spread to other areas of the body in adults whose disease has progressed after chemotherapy.

They said:

“Consultees, including the manufacturer, healthcare professionals and members of the public are now able to comment on the preliminary guidance. Comments received during this consultation will be fully considered by the Committee and following this meeting the next draft guidance will be issued.

“Until final guidance is issued, NHS bodies should make decisions locally on the funding of specific treatments. Once NICE issues its final guidance on a technology, it replaces local recommendations across the country.

 

Back to LaterLife Interest Index


Bookmark This Share on Facebook Receive more like this

 

Latest Articles:

Health food of the month: Sour bread

sour bread

One bread that has risen dramatically in popularity in recent years is sour bread and this should be of especial interest to our age group when many people start to suffer from digestive problems because it can reduce bloating and digestive discomfort.

more

AXA Health
Accept yourself

Couple smiling at each other

Our bodies go through many changes during our lives, but many of these changes are gradual, as a result of growing older. However, poor health can also alter the way we look and feel. Learning to live with and accept these differences can make the new us easier to adjust to.

more

Today preservatives are part of our everyday food

Packaged meat

Preservatives help to ensure we can buy a wide variety of food and drinks that are fresh and haven’t gone off. But how safe are all these additives?

more

Eat your way to good skin

Close up facial shot with scarf

A healthy diet can help combat the appearance of lines and blemishes.

more

Back to LaterLife Health Section

Visit our Pre-retirement Courses section here on laterlife or our dedicated Retirement Courses site

Bookmark


Advertise on laterlife.com



LaterLife Travel Insurance in Association with Avanti